Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Immunoglobulin Y anti-Helicobacter pylori** refers to an IgY-research program comprising orally administered, chicken egg-yolk-derived polyclonal IgY antibodies directed against *Helicobacter pylori*. The antibodies are generated by immunizing hens with *H. pylori* antigens and harvesting antigen-specific IgY from egg yolk. The intended mechanism is local neutralization of *H. pylori* in the gastrointestinal tract, including interference with bacterial virulence functions such as urease activity, thereby reducing colonization and infection burden. IgY-research has publicly described anti-*H. pylori* IgY work in human-health research materials, including dietary and functional-food studies; however, a distinct standardized pharmaceutical product, development code, formulation, and formal clinical phase are not publicly established. ([igy-research.com](https://igy-research.com/effect-of-dietary-anti-helicobacter-pylori-urease-immunoglobuline-y-on-helicobacter-pylori-infection/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on immunoglobulin Y (anti-Helicobacter pylori).